Real-world antidepressant prescription for patients with major depressive disorder in Japan: a Retrospective Cohort Study Using a Japanese Claim Database

Real-world antidepressant prescription for patients with major depressive disorder in Japan: a Retrospective Cohort Study Using a Japanese Claim Database - Real-world antidepressant prescription for patients with major depressive disorder in Japan: a Retrospective Cohort Study Using a Japanese Claim Database

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056181

Enrollment

179181

Registered

2024-11-18

Start date

2024-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder (MDD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Have a diagnosis code of MDD (ICD10= F32, 33) after November 2019. 2. Newly prescribed antidepressants after November 2019. 3. Age 18 years and older.

Exclusion criteria

Exclusion criteria: 1. No diagnostic code for MDD on index date. 2. Have schizophrenia diagnosis code on index date and look-back period 3. Antidepressants are prescribed during the look-back period. 4. Insufficient follow-up period (90 days after index date) . 5. Insufficient Look-back period (180 days back from index date).

Design outcomes

Primary

Measure	Time frame
The distribution of first-line antidepressant prescriptions among patients newly prescribed antidepressants after the launch of vortioxetine and patient characteristics that may influnce the choice of first-line antidepressant (gender, age, concomitant medications, comorbidities, etc.).	—

Secondary

Measure	Time frame
The treatment modification patterns (discontinuation, continuation, treatment change) within the first three months following the prescription of the first-line antidepressant and patient characteristics that may influence these patterns (gender, age, concomitant medications, comorbidities, etc.).	—

Countries

Japan

Contacts

Public ContactFumie Tokuda

Takeda Pharmaceutical Company Limited. Japan Medical Office

fumie.tokuda@takeda.com03-3242-1256

Outcome results